Back
Day Range
$25.82
$27.83
52-Week Range
$9.60
$30.58
Volume
1,533,123
50D / 200D Avg
$25.21
/
$21.69
Prev Close
$27.06
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -14.8 | 0.4 |
| P/B | 8.7 | 2.9 |
| ROE % | -73.9 | 3.8 |
| Net Margin % | — | 3.9 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.3 | 0.2 |
Analyst Price Target
Hold
$38.60
+48.8%
Low: $35.00
High: $42.00
Forward EPS
-$1.64
Est. Revenue
2.2 M
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2029 |
$0.32
$0.32 – $0.32
|
450 M | 4 |
| FY2028 |
-$1.14
-$2.88 – $1.20
|
170 M | 11 |
| FY2027 |
-$1.73
-$2.32 – -$1.13
|
23 M | 13 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
grant | 175,000 | — | — |
| Feb 1, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
other | 8,549 | $24.57 | $210,049 |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 10,000 | $9.53 | — |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 10,000 | $30.00 | $300,000 |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12,000 | $5.84 | — |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6,000 | $27.64 | $165,835 |
| Nov 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 593 | $24.90 | $14,766 |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40,000 | $5.84 | — |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20,000 | $22.00 | $440,000 |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40,000 | $5.84 | — |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20,000 | $20.01 | $400,102 |
| Aug 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 597 | $17.17 | $10,250 |
| Jul 29, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 8,322 | $15.23 | $126,751 |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
other | 20,000 | $3.85 | — |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
sell | 10,000 | $15.56 | $155,598 |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
other | 110,000 | $3.85 | — |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
sell | 55,000 | $15.92 | $875,600 |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12,000 | $5.84 | — |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6,000 | $14.93 | $89,567 |
| Jun 24, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 30,000 | $3.85 | — |
Key Takeaways
Debt/Equity of 0.29 — conservative balance sheet
Negative free cash flow of -142.09M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-73.93%
ROIC-29.07%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
0.29
Current Ratio9.25
Interest Coverage-19.93
Valuation
P/E Ratio
-14.79
P/B Ratio8.68
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100.00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -235.76M |
| ROE | -73.93% | ROA | -40.87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -142.09M |
| ROIC | -29.07% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.29 | Current Ratio | 9.25 |
| Interest Coverage | -19.93 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | -14.79 | P/B Ratio | 8.68 |
| P/S Ratio | N/A | PEG Ratio | -0.26 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 3.49B | Enterprise Value | 3.22B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 6.85M | 0.0 | 0.0 | 0.0 |
| Net Income | -235.76M | -151.09M | -216.21M | -381.90M | -10.66M |
| EPS (Diluted) | -2.06 | -1.57 | -2.31 | -4.24 | -0.08 |
| Gross Profit | 0.0 | 6.85M | 0.0 | 0.0 | 0.0 |
| Operating Income | -201.06M | -171.28M | -212.26M | -374.87M | -10.44M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 576.80M | 360.25M | 444.31M | 629.64M | 11.72M |
| Total Liabilities | 175.25M | 124.00M | 108.14M | 138.08M | 8.62M |
| Shareholders' Equity | 401.55M | 236.24M | 336.17M | 491.55M | 3.10M |
| Total Debt | 117.23M | 84.59M | 69.80M | 75.70M | 5.63M |
| Cash & Equivalents | 383.22M | 128.03M | 393.64M | 595.08M | 7.23M |
| Current Assets | 536.41M | 315.09M | 437.75M | 628.77M | 11.17M |
| Current Liabilities | 58.00M | 39.39M | 38.34M | 24.64M | 8.62M |